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The first analysis of the MRC RE01 trial in metastatic renal carcinoma identified a 28% reduction in the hazard of death for patients
treated with interferon-a compared with medroxyprogesterone acetate (MPA). No subgroup was identified in which treatment with
interferon-a was more or less effective than MPA. We used a new approach based on fractional polynomials to investigate the
updated data from this trial for the possible interaction of treatment with prognostic factors. In the spirit of hypothesis generation, we
considered 10 possible prognostic variables, of which white cell count (WCC) was found to influence the effectiveness of interferon
treatment. In patients treated with MPA, there was no prognostic effect of WCC, whereas, in patients treated with interferon, the risk
of dying increased significantly with WCC level. We defined subgroups of patients based on WCC levels and estimated a hazard ratio
of 0.53 in favour of interferon in patients with WCC o6.5 10
9, whereas for patients with WCC 410 10
9 the risk appears to be
similar between the treatment groups, or even slightly raised in the interferon group. Since our results are derived from flexible
statistical models, they may be interpreted as a new hypothesis and require validation in independent data.
British Journal of Cancer (2004) 90, 794–799. doi:10.1038/sj.bjc.6601622 www.bjcancer.com
& 2004 Cancer Research UK
Keywords: metastatic renal carcinoma; subgroup analysis; interactions; fractional polynomials; interferon
                                         
Between 1992 and 1997, 350 patients with metastatic renal
carcinoma were randomised to enter the MRC RE01 trial
comparing interferon-a with medroxyprogesterone acetate
(MPA) at 31 centres in the UK. In the first paper based on 335
patients and 236 deaths, a 28% reduction in the risk of death in the
interferon-a group was reported (MRCRCC, 1999). The trial was
stopped early, because the treatment effect crossed the effective-
ness boundary in a triangular sequential design. Owing to the side
effects of the interferon-a regimen, it is important to investigate
whether the clear overall survival advantage is present in all
patients. In the initial report (MRCRCC, 1999), there was no
evidence from w
2 tests of heterogeneity that any prognostic factor
had an influence on the effectiveness of interferon-a. Thus, no
subgroup was identified in which the treatment was more or less
effective.
Updated data with 322 deaths were analysed by using a new
approach to modelling interactions between treatment and
continuous covariates (Royston and Sauerbrei, 2003). We system-
atically investigated whether any of the potential prognostic factors
recorded at randomisation exhibits any predictive value, meaning
that the effect of treatment depends on such a factor.
Details of results on further end points such as progression-free
survival may be found in the first paper (MRCRCC, 1999). Here we
will consider only the primary end point of the trial, overall
survival. In this investigation, we considered age, WHO perfor-
mance status and other clinical and laboratory features listed in
Table 2. With the exception of weight loss, erythrocyte sedimenta-
tion rate (ESR) and nuclear grade, this list includes the ‘standard’
prognostic factors for advanced renal cell carcinoma (Elson, 2003).
The data were reanalysed, not to test a specific interaction
between treatment and a factor (if significant, often called a
predictive factor), but more with an emphasis on data exploration.
We used a statistical method based on fractional polynomials for
the investigation of potential predictive factors. It extends the
multivariable fractional polynomial (MFP) method used to
investigate the simultaneous prognostic effect of several contin-
uous factors. The main advantages of analysis of continuous
factors with fractional polynomials are to extract more information
from such factors, to improve the statistical power to detect
influential variables and their interaction with treatment
(Farewell et al, 2003), and to circumvent the problems of
arbitrary categorisation (Altman et al, 1994; Royston and
Altman, 1994; Sauerbrei and Royston, 1999; Royston and
Sauerbrei, 2003).
Clearly, the results of this unplanned analysis may only be
interpreted in a hypothesis-generating sense and the findings
require validation in independent data (Assmann et al, 2000).
PATIENTS AND METHODS
Patient characteristics and treatment
The principal eligibility criterion was a histologically or cytologi-
cally proven metastatic renal carcinoma in patients of WHO
Received 21 August 2003; revised 2 December 2003; accepted 3
December 2003
*Correspondence: Dr P Royston; E-mail: pr@ctu.mrc.ac.uk
British Journal of Cancer (2004) 90, 794–799
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lperformance status 0, 1 or 2 with at least one measurable
metastatic lesion. Patients were assigned at random to interfer-
on-a (Intron-A, Schering-Plough) 10MU, by subcutaneous injec-
tion three times per week for 12 weeks, or MPA (Provera, Upjohn)
300mg by mouth each day for 12 weeks. The present analysis is
based on data updated to June 2001.
Overall survival (OS) was calculated from the date of
randomisation to the date of death, irrespective of the cause of
death. The median follow-up time is 56 months. Of 350 patients
randomised, no follow-up information is available for three
patients. By June 2001, 322 (93%) patients were known to have
died.
Reasonably complete baseline data were available for the
following 14 potential prognostic factors: age, sex, nephrectomy
status, WHO performance status, time from initial diagnosis of
renal carcinoma to randomisation, time from diagnosis of
metastasis to randomisation, single/multiple sites of metastasis,
haemoglobin, white cell count, serum calcium, ESR, viscosity,
histopathological tumour grade and body weight.
For further details of patient characteristics, treatment and
follow-up, see MRCRCC (1999).
Statistical analysis
Before starting the analysis, we decided to include in the
investigation all potential prognostic factors for which the
proportion of missing values was less than 15%, yielding 10
variables. To maximise the statistical power by including all
patients in the multivariable analysis, we used the method
of van Buuren et al (1999) to impute the missing values.
As a sensitivity analysis, we repeated the multivariable analysis
for the subset of patients with complete data for all prognostic
variables.
The potential effects of prognostic factors were investigated in
univariate analyses. Continuous factors were modelled by using
fractional polynomials (Royston and Altman, 1994; Sauerbrei et al,
1999). All survival analyses and tests of hypotheses were conducted
within the Cox regression framework. P-values were based on the
partial likelihood ratio test. The proportional hazards assumption
was assessed by the Grambsch–Therneau test (Grambsch and
Therneau, 1994). The only variable showing violation of propor-
tional hazards was WHO performance status; however, this had no
major impact on the remaining analyses and is not considered
further.
A simultaneous assessment of the effects of prognostic factors
and of the predictive value of these factors (i.e. of their interaction
with treatment) was performed within a multiple regression
framework. We used the MFPI algorithm (an extension of the
MFP algorithm, see Appendix A) with a nominal P-value 0.05, to
determine the prognostic factors with influence on OS and to
investigate whether any of the 10 factors had a significant
interaction with treatment (i.e. are predictive factors).
As a check of any interactions identified by this method
and for the purpose of presentation, we divided the patients
into four groups, according to a categorisation of each predictive
factor. In the subgroups, comparison of the Kaplan–Meier curves
for the treatments and the corresponding estimates of the
treatment effect should broadly agree with the continuous function
representing the effect of treatment from the MFPI analysis. The
primary cut-point was chosen in a data-dependent fashion,
according to the function estimated by the MFPI analysis. Two
other cut-points were chosen among the quartiles of the
distribution of the predictive factor in question. This gives three
cut-points and four groups for each continuous variable.
Each analysis of interactions was adjusted for other prognostic
factors determined at the initial step by the MFPI algorithm (see
Appendix A).
RESULTS
The patients’ ages lay between 45 and 72 years (median 60). About
two-thirds were male. WHO performance status was one in about
50% of the patients and 0 and 2 in about 25% each. The median
time from first metastases to the date of randomisation was 1.2
months, and median time from primary diagnosis to randomisa-
tion was 3.2 months. In all, 57% had had a nephrectomy and 84%
of patients already had multiple metastases on entering the trial.
Further information on these variables including treatment details
may be found in the first report of the study. Table 1 gives details
of three variables not considered in the first report. All factors are
well balanced between the treatment groups. Missing values were
replaced with imputations to give complete data for analysis of
results from all 347 patients.
Table 2 shows the results of a univariate investigation of the
prognostic factors and of treatment. The estimated effect of
treatment changed little from the earlier analysis (MRCRCC, 1999).
The hazard ratio for the risk of dying, favouring interferon-a, was
0.75 (CI 0.60–0.93) compared with 0.72 before. The effect of
treatment is shown by Kaplan–Meier survival curves in Figure 1.
Of the prognostic factors investigated, WHO performance status,
haemoglobin, white cell count, time since metastases and time
since primary diagnosis showed a significant effect on the survival
time. Fractional polynomial analysis yielded significantly non-
linear functions for time from metastases to randomisation (log
transformation) and haemoglobin (reciprocal transformation).
Multivariable assessment of prognosis with deletion of non-
significant prognostic factors resulted in a model comprising
WHO performance status, haemoglobin, white cell count and time
from metastases to randomisation. All these variables were highly
significant in univariate analysis. The months since diagnosis and
serum calcium were significant in the univariate analysis, but no
longer so in the multivariable model (P40.5). After adjustment for
other factors, only the effect of time from metastases to
randomisation required a nonlinear function. The function (not
shown) suggests an elevated risk of death only for patients with
intervals from diagnosis of metastases of o3 months. A sensitivity
analysis using only the 306 patients with complete data on all
prognostic factors gave the same multivariable model.
Adjusting for factors in the multivariable model, we investigated
all the 10 prognostic variables given in Table 2 for a possible
interaction with treatment. A highly significant interaction was
found with white cell count (P¼0.0001, MFPI procedure). No
Table 1 Baseline characteristics of blood parameters
Characteristic MPA (n¼175) Interferon-a (n¼172)
Haemoglobin (gdl
 1)
o11 44 (25%) 46 (27%)
11–12.5 36 (21%) 52 (30%)
12.5–14 48 (27%) 31 (18%)
414 32 (18%) 35 (20%)
Unknown 15 (9%) 8 (5%)
White cell count ( 10
9l
 1)
o6.5 34 (19%) 47 (27%)
6.5–8 43 (25%) 41 (24%)
8–10 39 (22%) 40 (23%)
410 44 (25%) 36 (21%)
Unknown 15 (9%) 8 (5%)
Serum calcium (mmoll
 1)
o2.3 24 (14%) 40 (23%)
2.3–2.4 32 (18%) 27 (16%)
2.4–2.5 43 (25%) 49 (28%)
42.5 49 (28%) 42 (24%)
Unknown 27 (15%) 14 (8%)
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lfurther interactions were significant at the 5% level. Appendix B
gives the mathematical details of the interaction model. A
significant prognostic effect of WCC is seen only in the patients
treated with interferon. How the treatment effect of interferon-a
compared with MPA, estimated from our model, changes with the
patient’s white cell count is of considerable clinical relevance (see
Figure 2). For patients with very low white cell counts, the risk of
dying appears to be substantially reduced by interferon-a, whereas,
for those with values around 10, the risk seems to be similar for the
two treatments. For the 25% of patients with white cell count larger
than 10, interferon-a seems to be of no benefit, and the risk may
even be somewhat raised.
As a visual check of the results from our complex modelling
procedure, we divided the patients into four groups according to
white cell count, by using cut-points of 6.5, 8 and 10 10
9l
 1. The
value of 10 was chosen because the beneficial effect of treatment
disappears at about this point (Figure 2). The other two cut-points
represent the first two quartiles of the distribution of white cell
count. Figure 3 shows the estimated survival curves by treatment
in the four subgroups of white cell count.
In accordance with the function shown in Figure 2, a trend is
seen towards a substantial survival advantage of interferon-a in
group I with the lowest white cell counts, becoming weaker in
subgroups II and III with larger counts, and no longer present in
group IV. The estimated hazard ratios for the effect of interferon-a
in comparison to MPA (with 95% CI) are 0.53 (0.34–0.83), 0.69
(0.44–1.07), 0.89 (0.57–1.37) and 1.32 (0.85–2.05) in white cell
count groups I–IV, respectively. These estimates are little
influenced by adjustment for WHO performance status, haemo-
globin and time since metastases (details not given). In a
sensitivity analysis using only the 306 patients with complete data
on all prognostic factors, the principal results described above
were confirmed.
DISCUSSION
The first report of the MRC RE01 study (MRCRCC, 1999) showed
that interferon-a prolongs survival, but no factors predictive of
response to treatment with interferon-a were identified. Owing to
the toxicity profile of interferon-a and its acceptance as standard
therapy for metastatic RCC in the UK, it is important to investigate
whether all patients in fact benefit from this therapy. With the data
updated to June 2001, we confirmed the overall treatment effect.
More importantly, we were able to identify an interaction between
treatment and white cell count. The statistical power of this new
analysis is improved, since the number of events (deaths) is 36%
greater than before. Furthermore, we used a new approach to
investigate interactions. The usual approach of categorising
continuous variables reduces the power, and, more importantly,
the results depend on the choice of a ‘suitable’ cut-point. By
contrast, the MFPI approach estimates functions to describe the
Table 2 Univariate analysis of prognostic factors and treatment (Cox
regression)
Characteristic b s.e. P-value
Age
a 0.0026 0.0053 0.6
Sex
Male 0 — 0.8
Female  0.04 0.12
WHO performance status
00 — o0.001
b
1 0.32 0.14
2 1.12 0.16
Months since first diagnosis of renal
carcinoma
a
 0.0040 0.0016 0.02
Transformed months since first diagnosis of
metastases
c
 0.19 0.04 o0.001
Nephrectomy
No 0 — 0.07
Yes  0.21 0.11
Metastases
Single 0 — 0.3
Multiple 0.17 0.15
Transformed haemoglobin
d 35.9 4.4 o0.001
White cell count
a 0.087 0.013 o0.001
Serum calcium
a 0.99 0.29 0.001
Treatment
MPA 0 — 0.009
Interferon-a  0.29 0.11
Values of b are log hazard ratios. s.e.¼standard error.
aLinear function.
bTrend test.
cLog transformation.
d1/haemoglobin.
At risk 1: 175 55 22 11
At risk 2: 172 73 36 20
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Figure 1 Kaplan–Meier estimates of overall survival by treatment group.
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Figure 2 Dependence on white cell count ( 10
9l
 1) of the effect of
treatment with interferon-a compared with MPA, estimated from fractional
polynomial model. Solid line: hazard ratio; dashed lines: 95% CI for hazard
ratio. The horizontal line at hazard ratio¼1 denotes equivalence of
treatment effects. Values beneath this line indicate that interferon-a is more
effective than MPA, and vice versa. A bar chart showing the distribution of
white cell count values for all patients in the study is superimposed.
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linfluence of the variable in question on the outcome in each
treatment group, and does not require the selection of any cut-
points.
As in the first report, we investigated the prognostic and
predictive value of sex, age, performance status, time since
diagnosis of renal carcinoma, time since diagnosis of metastases,
nephrectomy status and number of metastatic sites (single/
multiple). In addition, the prognostic and predictive value of
haemoglobin, white cell count and serum calcium were investi-
gated. For these measurements, we handled the issue of data
missing in some patients by using an imputation approach (van
Buuren et al, 1999). By multivariable modelling with the MFP
approach, we identified haemoglobin and white cell count as
strong prognostic factors in addition to WHO performance status
and time from metastases to randomisation. With the MFPI
approach, white cell count was identified also as a predictive
factor. The level of white cell count appears to influence the
effectiveness of treatment with interferon-a (Figures 2 and 3).
Patients with low white cell counts seem to have a reduced risk of
dying following interferon-a treatment, but the risk increases with
the count. By contrast, the estimated risk function for MPA
changes little with a change in white cell count.
An understanding of the relationship between the pretreatment
white cell count and the risk of dying following interferon
treatment is hampered by limited knowledge of the mechanism
of action of interferon. A number of possible anticancer
mechanisms have been proposed, including direct antiproliferative
effects, modulation of class I and II MHC antigen expression,
enhanced natural killer (NK) cell activity, modulation of
haematopoiesis and inhibition of angiogenesis (Small and Motzer,
2003).
Negative regulation of host cytotoxicity has been reported to be
mediated by certain prostaglandins and a variety of cell types
including macrophages and neutrophils (Kimber and Moore,
1985). It is possible that some patients in our study had raised
white cell counts as a result of raised neutrophil counts, and that
these cells are responsible for blocking cytotoxic enhancement by
the interferon. Lymphopaenia has been shown to correlate with
advanced disease stage in Hodgkin’s disease. It is not clear if the
lymphopaenia is due to lymphocyte trafficking to sites of disease
or to an absolute quantitative deficiency (Ayoub et al, 1999).
Unfortunately, our database recorded only the total white cell
count; we did not have data on the constituent neutrophil and
lymphocyte counts. Our hypothesis that adverse outcome is
associated with raised neutrophil counts will be tested by more
detailed analyses of the peripheral blood white cells in future
interferon studies. Longitudinal studies, of the effect of interferon
therapy on white cell subpopulations in peripheral blood and
within tumour tissue, may also provide clues to the mechanism of
action.
In previous studies, various prognostic factors have been
identified as important indicators for survival of patients with
metastatic renal cell carcinoma. These include performance status,
recent weight loss, disease-free interval, pretreatment ESR, lactate
dehydrogenase (LDH), neutrophils, haemoglobin, extrapulmonary
and bone metastases, and the number of metastatic sites (Elson
et al, 1988; Palmer et al, 1992; Lopez-Ha ¨nninen et al, 1996; Gelb,
1997; Culine et al, 1998; Hoffmann et al, 1999; Motzer et al, 1999,
2002). A recent study of 425 good performance status patients
added C-reactive protein (CRP) to this list and presented a model
based on neutrophils, CRP, LDH, time from primary diagnosis to
metastases, number of metastatic sites and presence of bone
metastases (Atzpodien et al, 2003). Negrier et al (2002) analysed
the details of 782 patients enrolled in successive multicentre trials
using cytokine regimens. They found that biological signs of
inflammation, an interval of less than 1 year from diagnosis to
metastases, elevated neutrophil counts, liver metastases, bone
metastases, performance status, the number of metastatic sites,
alkaline phosphatase and haemoglobin levels were predictive of
survival outcome. Elevated neutrophil counts were also identified
as one of four predictors of rapid progression of the disease.
However, as with many diseases, a great many prognostic factors
are proposed, but most await confirmation of their importance in
the context of a multivariable model.
As with all complex and flexible statistical modelling proce-
dures, the MFPI approach may sometimes produce results which
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Figure 3 Survival by subgroups I–IV of white cell count ( 10
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 1). Definition of groups according to white cell count: I: o6.5; II: 6.5–8; III: 8 – 10; IV:
410. Solid lines: interferon-a group; dashed lines: MPA group.
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lare strongly influenced by pecularities in the data, for example,
outliers or influential points (Belsley et al, 1980). Single patients or
a small group of patients may determine the shape of the function
or seriously influence the P-value of a test statistic. Therefore, a
check of the main results and a sensitivity analysis of the major
assumptions are required. In our analysis of interactions, we found
that two extreme values of white cell count (37.1 and 55.2 10
9l
 1)
determined the shape of the function in a region of no interest
(white cell count 425, function not shown) and influenced the P-
value for interaction. On deleting these extreme cases, the P-value
changed from 0.0001 to 0.008, still strong evidence of an
interaction between treatment and white cell count. The more
essential check of the functions proposed is to verify the result
from MFPI, by considering treatment comparisons within
subgroups derived by inspecting the MFPI functions. The
subgroups have an order allowing a sensible check of the
continuous function postulated for the treatment effect. A
comparison of the treatment effects across four subgroups defined
by white cell count clearly demonstrates that the interaction
postulated by our model is not a statistical artefact.
Despite the checks considered in the paper, the interaction
between treatment and white cell count can only be interpreted in
a hypothesis-generating sense (Assmann et al, 2000). This analysis
was not planned in advance, and we investigated as many as 10
factors for possible interaction with treatment. The interaction
found in our data may conceivably be due to chance, and needs
validation in independent studies before it can confidently be used
to guide treatment decisions. If our finding is confirmed, the
usefulness of treatment with interferon-a has to be questioned for
patients with higher white cell counts. Confirmation of the
prognostic role of white cell count in patients treated with
interferon-a may be obtained when results are available from the
ongoing RE04 trial of interferon monotherapy vs the Atzpodien
triple regimen (interferon-a, interleukin-2 and 5-fluorouracil) in
patients with good WHO performance status.
The potential outcome of the findings of this study is that a
simple, widely available laboratory test may be able to select
patients likely to benefit from interferon therapy. Clearly, much
further investigation of the mechanism of action of interferon is
required 20 years after its initial use in renal cancer (Quesada et al,
1983).
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lAppendix A: The MFPI algorithm
Royston and Sauerbrei (2003) proposed a method of analysing
treatment/prognostic factor interactions with data from clinical
trials. The analysis of interactions with categorical variables such
as sex and performance status is well established and reasonably
straightforward. Typically, in survival data, the hypothesis test of
no interaction is assessed within a Cox model or by a stratified
logrank test, and the hazard ratio for the treatment effect and its CI
is estimated at each level of the prognostic factor. In a situation
with no predefined hypothesis, P-value adjustment for multiple
testing may be made to counteract the inflated probability of a type
I error.
How to approach such an analysis for a continuous prognostic
factor is not so simple. The conventional method has been to
categorise the factor into two or more groups and apply the
analysis just described, perhaps with a suitable test for trend.
However, this method may lack power (Farewell et al, 2003) and
the results will depend on the choice of cut-point(s). Alternatively,
linearity may be assumed and the slopes may be compared, but
power will again be lost if the relationship is not in fact linear.
The MFPI algorithm is based on fractional polynomial analysis
of continuous predictors (Royston and Altman, 1994; Sauerbrei
et al, 1999) and is an extension of the MFP algorithm of Sauerbrei
and Royston (1999). In the MFP algorithm, continuous predictors
are subject to possible transformations including logarithm,
square root, etc, or to two such transformations, giving a fractional
polynomial model of degree 2 (FP2) (see Sauerbrei et al (1999) for
an example in breast cancer explaining fractional polynomial
analysis in detail). Transformation(s) are applied only if the fit of
the model is significantly improved, the default being a linear
model. Each predictor is examined in turn and the process stops
when no change in the required transformation takes place. At the
same time, a predictor may be eliminated from the model if it is
not statistically significant.
The MFPI algorithm proceeds in two stages. First, a multi-
variable adjustment model is developed from all the available
prognostic factors by using the MFP algorithm as just outlined.
Then, each candidate continuous factor is modelled by an FP2
function in each treatment group, allowing for possible confound-
ing by including the variables of the adjustment model. This
approach allows the functional influence of the factor to differ by
treatment group, and is equivalent to saying that the treatment
effect varies continuously with the level of the prognostic factor.
For the purposes of presentation, two graphs may be given. The
first graph shows the estimated function in each treatment group.
The second (the more important) shows the difference between the
estimated functions, which, as just mentioned, is a representation
of the continuously varying treatment effect. These graphs will
often suggest natural cut-point(s) on the factor, which should be
confirmed by Kaplan–Meier plots of survival probabilities
according to the groups defined by the cut-point(s).
Appendix B: Further details of the interaction model
The MFPI procedure indicated a fractional polynomial transfor-
mation with powers 2 and 3 for white cell count (WCC, x), of the
form b1x
2þb2x
3. The equations for log hazard ratio (log HR)
derived from the interaction model are as follows (standard errors
are in parentheses). In the MPA treatment group:
LogHR ¼0:31ð0:14Þ ðWHOPS1Þþ0:90ð0:16Þ ðWHOPS2Þ
þ 1:42ð0:34Þ ðtimefrommetastasesÞ
 0:5
  0:20ð0:03Þ haemoglobin þ 0:19ð0:21Þ ðWCC=10Þ
2
  0:0089ð0:04Þ ðWCC=10Þ
3
In the interferon-treated group:
LogHR ¼ 0:94ð0:23Þþ0:31ð0:14Þ ðWHOPS1Þ
þ 0:90ð0:16Þ ðWHOPS2Þ
þ 1:42ð0:34Þ
 ðtimefrommetastasesÞ
 0:5
  0:20ð0:03Þ haemoglobin
þ 1:34ð0:25Þ ðWCC=10Þ
2   0:33ð0:07Þ ðWCC=10Þ
3
The division of WCC by 10 in the above formulas makes them
more readable, but has no effect on the functions estimated for
WCC. As may be judged by comparing the regression coefficients
for (WCC/10)
2 and (WCC/10)
3 with their respective standard
errors, a significant prognostic effect of WCC is seen only in the
patients treated with interferon.
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